Epigenetic mechanism of survivin dysregulation in human cancer
Survivin (coding gene BIRC5) is a dual functional protein acting as a critical inhibitor of apoptosis (IAP) and key regulator of cell cycle progression. It is usually produced in embryonic tissues during development and undetectable in most adult tissues. Overexpression of Survivin frequently occurs in various human cancers and increased Survivin correlates with poor clinic outcome, tumor recurrence, and therapeutic resistance. Because of its selective expression in tumor, but not normal tissues, Survivin has been recognized as an attractive target for cancer treatment. Although several therapeutic approaches targeting Survivin are actively under clinical trials in human cancers, to date no Survivin-targeted therapy has been approved for cancer treatment. Numerous studies have devoted to uncovering the underlying mechanism resulting in Survivin dysregulation at multiple levels, such as transcriptional and post-transcriptional regulation. The current article provides a literature review on the transcriptional and epigenetic regulation of Survivin expression in human cancers. We focus on the impact of DNA methylation and histone modifications, including specific lysine methylation, demethylation, and acetylation on the expression of Survivin. The latest development of epigenetic approaches targeting Survivin for cancer treatment are also discussed.
KeywordsSurvivin epigenetics DNA methylation histone modification cancer therapy
Unable to display preview. Download preview PDF.
This work was supported by the National Institutes of Health/National Cancer Institute (NIH/NCI) (R01CA201011) and the National Natural Science Foundation of China (81472763 to Bolin Liu).
- Acquati, S., Greco, A., Licastro, D., Bhagat, H., Ceric, D., Rossini, Z., Grieve, J., Shaked-Rabi, M., Henriquez, N.V., Brandner, S., Stupka, E., and Marino, S. (2013). Epigenetic regulation of survivin by Bmi1 is cell type specific during corticogenesis and in gliomas. Stem Cells 31, 190–202.CrossRefPubMedGoogle Scholar
- Angileri, F.F., Aguennouz, M.H., Conti, A., La Torre, D., Cardali, S., Crupi, R., Tomasello, C., Germanò, A., Vita, G., and Tomasello, F. (2008). Nuclear factor-?B activation and differential expression of survivin and Bcl-2 in human grade 2–4 astrocytomas. Cancer 112, 2258–2266.CrossRefPubMedGoogle Scholar
- Berrada, N., Amzazi, S., Ameziane El Hassani, R., Benbacer, L., El Mzibri, M., Khyatti, M., Chafiki, J., Abbar, M., Al Bouzidi, A., Ameur, A., and Attaleb, M. (2012). Epigenetic alterations of adenomatous polyposis coli (APC), retinoic acid receptor beta (RARbeta) and survivin genes in tumor tissues and voided urine of bladder cancer patients. Cell Mol Biol (Noisy-le-grand) Suppl. 58, OL1744–1751.Google Scholar
- Cheng, Q., Ling, X., Haller, A., Nakahara, T., Yamanaka, K., Kita, A., Koutoku, H., Takeuchi, M., Brattain, M.G., and Li, F. (2012). Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol 3, 179–197.PubMedPubMedCentralGoogle Scholar
- Hervouet, E., Debien, E., Campion, L., Charbord, J., Menanteau, J., Vallette, F.M., and Cartron, P.F. (2009). Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA Repeats element and genes governing apoptosis and proliferation. Clin Cancer Res 15, 3519–3529.CrossRefPubMedGoogle Scholar
- Li, F., and Altieri, D.C. (1999). Transcriptional analysis of human survivin gene expression. Biochem J 344 Pt 2, 305–311.Google Scholar
- Vaziri, S.A.J., Hill, J., Chikamori, K., Grabowski, D.R., Takigawa, N., Chawla-Sarkar, M., Rybicki, L.R., Gudkov, A.V., Mekhail, T., Bukowski, R.M., Ganapathi, M.K., and Ganapathi, R. (2005). Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3 and survivin. Mol Cancer Ther 4, 1880–1890.CrossRefPubMedGoogle Scholar
- Wang, S., Zhu, L., Zuo, W., Zeng, Z., Huang, L., Lin, F., Lin, R., Wang, J., Lu, J., Wang, Q., Lin, L., Dong, H., Wu, W., Zheng, K., Cai, J., Yang, S., Ma, Y., Ye, S., Liu, W., Yu, Y., Tan, J., and Liu, B. (2016). MicroRNA- mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer. Oncotarget 7, 37693–37713.PubMedPubMedCentralGoogle Scholar
- Weiss, A., Heinz, C., and Groner, B. (2008). Survivin—An inhibitor of apoptosis as a target for peptide based therapy for human breast cancer. J Pept Sci 14, 125–125.Google Scholar
- Yu, J., Zhang, H., Gu, J., Lin, S., Li, J., Lu, W., Wang, Y., and Zhu, J. (2004). Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 4, 65.CrossRefPubMedPubMedCentralGoogle Scholar
- Zhang, Y., Chen, H., Zhou, S., Wang, S., Zheng, K., Xu, D., Liu, Y., Wang, X., Wang, X., Yan, H.Z., Zhang, L., Liu, Q., Chen, W., and Wang, Y. (2015). Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway. Mol Cancer 14, 56.CrossRefPubMedPubMedCentralGoogle Scholar